Brokerages Anticipate Achaogen Inc (AKAO) Will Post Quarterly Sales of $4.05 Million
Analysts forecast that Achaogen Inc (NASDAQ:AKAO) will announce $4.05 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Achaogen’s earnings, with estimates ranging from $2.00 million to $7.22 million. Achaogen reported sales of $580,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 598.3%. The company is scheduled to report its next earnings report on Wednesday, November 14th.
On average, analysts expect that Achaogen will report full year sales of $14.85 million for the current financial year, with estimates ranging from $9.13 million to $21.50 million. For the next year, analysts expect that the business will post sales of $47.21 million per share, with estimates ranging from $26.49 million to $87.72 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last issued its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.19). Achaogen had a negative return on equity of 146.50% and a negative net margin of 2,286.21%. The company had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million.
NASDAQ AKAO traded down $0.11 during trading hours on Thursday, hitting $4.20. 4,660,207 shares of the company were exchanged, compared to its average volume of 654,036. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.79 and a quick ratio of 3.79. Achaogen has a 52 week low of $4.06 and a 52 week high of $16.49.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA bought a new position in shares of Achaogen during the second quarter valued at approximately $1,220,000. Bank of America Corp DE grew its stake in shares of Achaogen by 274.7% during the second quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock valued at $1,717,000 after buying an additional 145,305 shares during the last quarter. Teton Advisors Inc. grew its stake in shares of Achaogen by 324.2% during the second quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock valued at $1,212,000 after buying an additional 107,000 shares during the last quarter. Gamco Investors INC. ET AL grew its stake in shares of Achaogen by 43.1% during the second quarter. Gamco Investors INC. ET AL now owns 94,700 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 28,500 shares during the last quarter. Finally, Gabelli Funds LLC grew its stake in shares of Achaogen by 18.6% during the second quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock valued at $1,787,000 after buying an additional 32,400 shares during the last quarter. 60.61% of the stock is currently owned by hedge funds and other institutional investors.
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Featured Article: Market Capitalization – What it Means for Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.